Source link : https://www.newshealth.biz/health-news/vedolizumab-shows-greater-persistence-than-tofacitinib-in-uc/
STOCKHOLM, Sweden — The monoclonal antibody vedolizumab (Entyvio, Takeda) showed significantly greater treatment persistence than tofacitinib (Xeljanz, Pfizer), a small-molecule Janus kinase (JAK) inhibitor, in bio-naive patients with ulcerative colitis (UC), according to a retrospective study. Steroid-free clinical remission was also higher in patients on vedolizumab at week 12, although rates of biochemical and fecal […]
Author : News Health
Publish date : 2024-02-28 11:21:08
Copyright for syndicated content belongs to the linked Source.
Categories